Lupin Limited — Updates, 16-06-2025: Press Release

Lupin has entered a license and supply deal with Sino Universal Pharmaceuticals for Tiotropium Dry Powder Inhaler (18 mcg) in China, targeting COPD. Lupin will manufacture and hold marketing rights, while SUP will handle regulatory approvals and sales. This collaboration boosts Lupin’s footprint in China’s expanding respiratory market, enhancing its access to respiratory healthcare patients.